Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Virpax Pharmicals表示，3月15日收到納斯達克的來信，稱該公司已恢復遵守上市規則5550（A）（2）
Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Virpax Pharmicals表示，3月15日收到納斯達克的來信，稱該公司已恢復遵守上市規則5550（A）（2）
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。